QQQ   427.93 (-0.74%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.93 (-0.74%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.93 (-0.74%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.93 (-0.74%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

$1.85
-0.06 (-3.14%)
(As of 01:57 PM ET)

Esperion Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$9.33
404.50% Upside
High Forecast$16.00
Average Forecast$9.33
Low Forecast$4.00
TypeCurrent Forecast
4/18/23 to 4/17/24
1 Month Ago
3/19/23 to 3/18/24
3 Months Ago
1/18/23 to 1/18/24
1 Year Ago
4/18/22 to 4/18/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$9.33$9.33$10.75$11.17
Predicted Upside404.50% Upside282.83% Upside161.42% Upside136.76% Upside
Get Esperion Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

ESPR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ESPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Esperion Therapeutics Stock vs. The Competition

TypeEsperion TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside407.25% Upside938.66% Upside12.13% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$8.00+186.74%
3/25/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$16.00+492.59%
1/3/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
8/1/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnder Perform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:14 PM ET.

ESPR Price Target - Frequently Asked Questions

What is Esperion Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Esperion Therapeutics stock is Hold based on the current 3 hold ratings and 2 buy ratings for ESPR. The average twelve-month price prediction for Esperion Therapeutics is $9.33 with a high price target of $16.00 and a low price target of $4.00. Learn more on ESPR's analyst rating history.

Do Wall Street analysts like Esperion Therapeutics more than its competitors?

Analysts like Esperion Therapeutics less than other Medical companies. The consensus rating for Esperion Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ESPR compares to other companies.

Does Esperion Therapeutics's stock price have much upside?

According to analysts, Esperion Therapeutics's stock has a predicted upside of 282.20% based on their 12-month stock forecasts.

What analysts cover Esperion Therapeutics?

Esperion Therapeutics has been rated by HC Wainwright, and Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ESPR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners